APRI News Alert Apricus Biosciences Inc (APRI) 1.01 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Apricus Biosciences Inc (APRI) 1.01 $APRI

Apricus Biosciences And Vitaros: Update On The Launch
MTF Investing - at Seeking Alpha - Wed Dec 24, 12:21PM CST

APRI: 1.01 (+0.03)

Apricus Biosciences Announces Year-End 2014 Update and 2015 Plans to Advance Its Clinical Pipeline and Further Commercialize Its Erectile Dysfunction Drug Vitaros(R)
GlobeNewswire - Mon Dec 22, 6:30AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reviewed its 2014 corporate progress and its clinical development and commercialization plans for 2015.
APRI: 1.01 (+0.03)

New medical chief at Apricus
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 9:52AM CST

APRI: 1.01 (+0.03)

Apricus Biosciences Appoints Barbara Troupin, M.D. as Chief Medical Officer
GlobeNewswire - Mon Dec 15, 6:39AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the appointment of Barbara Troupin, M.D., as the Company's Chief Medical Officer. Dr. Troupin brings to Apricus over 15 years of experience in the areas of pharmaceutical clinical development and medical affairs. She will report to Richard Pascoe, Apricus' Chief Executive Officer, and her appointment is effective immediately.
APRI: 1.01 (+0.03)

Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa(TM) in Patients With Raynaud's Phenomenon
GlobeNewswire - Thu Dec 04, 7:06AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the first patient has been enrolled in the Phase 2a clinical trial to evaluate RayVa, Apricus' product candidate for the treatment of Raynaud's phenomenon secondary to scleroderma. RayVa combines alprostadil, a potent vasodilator, with Apricus' proprietary permeation enhancer DDAIP.HCl, and is applied as an on-demand topical cream to affected extremities.
APRI: 1.01 (+0.03)

Apricus Biosciences names Brian T. Dorsey as its chief development officer
M2 - Wed Dec 03, 7:08AM CST
Biopharmaceutical company Apricus Biosciences (NasdaqCM:APRI) revealed on Tuesday the election of Brian T. Dorsey as its chief development officer.
APRI: 1.01 (+0.03)

Apricus Biosciences Appoints Brian T. Dorsey as Chief Development Officer
GlobeNewswire - Tue Dec 02, 6:30AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the appointment of Brian T. Dorsey as the Company's Chief Development Officer, a newly established position. Mr. Dorsey brings to Apricus over 20 years of experience in the pharmaceutical industry across early- and late-stage development programs, as well as with marketed products. He will report to Richard Pascoe, Apricus' Chief Executive Officer. His appointment is effective immediately.
APRI: 1.01 (+0.03)

Apricus Biosciences' (APRI) CEO Rich Pascoe on Q3 2014 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 11:29AM CST

APRI: 1.01 (+0.03)

Apricus Biosciences beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:55AM CST

APRI: 1.01 (+0.03)

Apricus Biosciences Announces Third Quarter 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Mon Nov 10, 6:07AM CST
Company Recently Expanded Development Pipeline with U.S. In-License of Fispemifene
APRI: 1.01 (+0.03)

Apricus Biosciences to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Monday, November 10, 2014
ACCESSWIRE - Fri Nov 07, 3:06PM CST
SAN DIEGO, CA / ACCESSWIRE / November 7, 2014 / Apricus Biosciences, Inc. (NASDAQ:APRI) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Monday, November 10, 2014 at 8:30 AM Eastern Time.
APRI: 1.01 (+0.03)

Apricus Biosciences to Present at Three Upcoming Investor Conferences in November and December of 2014
GlobeNewswire - Wed Nov 05, 6:46AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), a developer of biopharmaceutical therapeutics for urology and rheumatology disorders, today announced that members of senior management will present at the following three investor conferences, each of which will be webcast live and for replay at http://www.apricusbio.com/investor-relations/presentations/.
APRI: 1.01 (+0.03)

Apricus Biosciences Announces Corporate Update and Third Quarter 2014 Financial Results Conference Call
GlobeNewswire - Tue Nov 04, 6:30AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced that the Company's third quarter financial results will be released on Monday, November 10, 2014. Company management will host a conference call on Monday, November 10, 2014, at 8:30 a.m. Eastern Time to discuss the financial results and other recent corporate highlights.
APRI: 1.01 (+0.03)

Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Belgium by Sandoz
GlobeNewswire - Mon Nov 03, 5:00AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced the launch of Vytaros in Belgium by the Sandoz Division of the Novartis Group of Companies ("Sandoz" . Apricus' novel topical on-demand treatment for erectile dysfunction ("ED" , being marketed in Belgium as Vytaros, is also marketed in other European countries as Vitaros. Belgium will be the third territory in which Sandoz is launching the product in the European Union (the "EU" , following successful launches by Apricus' partners Takeda in the United Kingdom (the "UK" , and by Sandoz in Germany and Sweden. The product is currently approved in ten countries in Europe, including major ED markets such as the aforementioned and France, Italy and Spain. The Company expects additional launches by its partners in these approved countries into 2015.
APRI: 1.01 (+0.03)

Apricus Expands Development Pipeline With the In-Licensing of U.S. Rights for Fispemifene, a Phase 2b Ready Asset, From Forendo Pharma Targeting Urological Conditions in Men
GlobeNewswire - Mon Oct 20, 1:00AM CDT
-- Apricus Funds Upfront License Fee and 2015 Phase 2b Development Cost with $10 Million Venture Debt Financing --
APRI: 1.01 (+0.03)

Apricus Biosciences wins notice of allowance in the US for patent application for RayVa
M2 - Tue Oct 14, 7:23AM CDT
Biopharmaceutical company Apricus Biosciences (NasdaqCM:APRI) revealed on Monday the receipt of the US Patent and Trademark Office's (USPTO) Notice of Allowance for RayVa for treating Raynaud's phenomenon in the US.
APRI: 1.01 (+0.03)

Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa(TM)
GlobeNewswire - Mon Oct 13, 6:09AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 14/110,348 (the '348 application). The patent application generally is directed to methods and compositions for treating Raynaud's phenomenon, including claims related to treating Raynaud's phenomenon that is secondary to systemic sclerosis.
APRI: 1.01 (+0.03)

Apricus Biosciences to Present at the 13th Annual BIO Investor Forum
GlobeNewswire - Wed Oct 01, 9:21AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced that Richard Pascoe, Chief Executive Officer, will present at the 13 Annual BIO Investor Forum on Wednesday, October 8, 2014 at 11:30 a.m. Pacific Time. The meeting will be held at the Palace Hotel in San Francisco, CA. Mr. Pascoe will provide an update on the successful European launch of Vitaros, the Company's topical treatment for erectile dysfunction. Mr. Pascoe will also provide an overview of the Apricus drug candidate, RayVa, targeted to treat the circulatory condition Raynaud's phenomenon.
APRI: 1.01 (+0.03)

Apricus CEO to Discuss Company's Drug Portfolio, Including Its Topical Cream for Erectile Dysfunction, Vitaros(R), LIVE on iHeart (Clear Channel) Business Talk Radio DFW 1190AM on Sept. 25, 2014
Marketwire - Wed Sep 24, 1:36PM CDT
Richard Pascoe, CEO of biopharmaceutical developer, Apricus Biosciences, Inc. (NASDAQ: APRI) will be interviewed live tomorrow on iHeart (Clear Channel) Business Talk Radio. Mr. Pascoe will discuss the Company's prescription erectile dysfunction treatment Vitaros(R), which was launched commercially in the UK, Germany and Sweden this year and is expected to roll out in other European countries later this year and in 2015. He will also review Apricus' development portfolio, which includes drug candidate RayVa(TM) targeted to treat the circulatory condition, Raynaud's phenomenon secondary to scleroderma. Raynaud's affects the extremities in an estimated 3 - 5% of the U.S. population. Femprox(R), Apricus' third drug candidate, is targeted for the treatment of female sexual interest / arousal disorder.
APRI: 1.01 (+0.03)

Female Hypoactive Sexual Desire Disorder Therapeutics Pipeline Review, H2 2014 - 3 Companies & 7 Drug Profiles
M2 - Wed Sep 24, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cpm6jv/female_hypoactive) has announced the addition of the "Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Female Hypoactive Sexual Desire Disorder and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Female Hypoactive Sexual Desire Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Apricus Biosciences, Inc. - Palatin Technologies, Inc. - ANI Pharmaceuticals, Inc. Drug Profiles - flibanserin - testosterone - alprostadil - bremelanotide - (sildenafil testosterone) - (bupropion hydrochloride trazodone hydrochloride) - (buspirone hydrochloride testosterone) For more information visit http://www.researchandmarkets.com/research/cp...hypoactive
ANIP: 55.24 (+1.79), PTN: 0.71 (+0.04), APRI: 1.01 (+0.03)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 61

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 53

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 51

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 67

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 22

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Holland America Tests Asia Demand With Eurodam Debut

Updated Category News Views 128

Cherry blossoms are not normally the sort of thing that gets my investor blood moving, but a ship deployment decision does. Holland America Line is sending Eurodam into Asia for its first season there from September 2028 through May 2029, and it is plainly trying to sell more than transportation between postcard ports. The pitch is time: five new ports, 14 ports with...

Continue Reading

Top 5 Most Recently Viewed Articles

InsCorp, Inc. Experiences Significant Growth Impact in 2025

Updated Category News Views 229

InsCorp, Inc. Sees Improved Financial Metrics in 2025 InsCorp, Inc. (OTCQX: IBTN) has announced results for the second quarter of 2025, demonstrating a noticeable upward trend in earnings per share (EPS) at $0.73, an increase from $0.57 in the prior quarter and $0.63 over the same period last year. Jim Rieniets, the President and CEO of INSBANK, expressed optimism about...

Continue Reading
Revance Celebrates National Sunscreen Day with Times Square Billboard

Updated Category News Views 223

Revance Celebrates National Sunscreen Day with a Bold Message Revance is thrilled to commemorate National Sunscreen Day with a vibrant digital billboard in Times Square. This event not only marks a celebration of Blue Lizard® Australian Sunscreen but also highlights the importance of sun safety as the summer season approaches. Blue Lizard is recognized as the leading...

Continue Reading
Exploring Noah Holdings' Strategic Vision for Global Growth

Updated Category News Views 523

Noah's Global Expansion and Innovative Services Noah Holdings has actively pushed the envelope in providing innovative financial services tailored to meet the diverse wealth management requirements of its clients. This year marks a significant chapter in their journey toward international expansion, where they are introducing groundbreaking solutions along with targeted...

Continue Reading
Streamline Your Taxes: Harness QuickBooks Reports Now

Updated Category News Views 21

QuickBooks: Not Just for Bookkeeping Anymore Taxes can be a pain, but if you're rocking QuickBooks, there's a silver lining. Karen Eberhart Metcalfe, the accounting whiz from Bolingbrook, IL, assures us that this tool isn't merely for ticking boxes in bookkeeping; it's your ace for navigating tax season with less sweat and more precision. When you’ve got those reports...

Continue Reading
Vistra's Options Trading Insights: What Big Investors Indicate

Updated Category News Views 177

Understanding Vistra's Options Trading Landscape Investors are closely observing the options trading activity for Vistra (NYSE: VST) as it indicates a notable bearish sentiment among significant traders. Retail traders would benefit from being aware of these trends. Current Market Sentiment Recent data revealed on options trading history highlights that a recognizable...

Continue Reading